Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

Abstract Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor
(HER2)–targeted antibody-drug conjugate, composed of trastuzumab, a stable thioether …

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the
antitumor properties of the humanized anti-human epidermal growth factor receptor 2 …

abstract Protein therapeutics represent a diverse array of biologics including antibodies,
fusion proteins, and therapeutic replacement enzymes. Since their inception, they have …

Antibody–drug conjugates (ADCs) are monoclonal antibodies with covalently bound
cytotoxic drugs. They are designed to target tumor antigens selectively and offer the hope of …

Antibody–drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of
monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes …

Despite considerable effort, application of monoclonal antibody technology has had only
modest success in improving treatment outcomes in patients with solid tumours. Enhancing …

Major advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have
created revolutionary drug delivery systems in cancer over the past decade. While these …

Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for
cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA …

The concept of treating cancer with antibody-drug conjugates (ADCs) has gained
momentum with the favorable activity and safety of trastuzumab emtansine (T-DM1) …